• Contact
  • EPAD Academy
Top Bar Menu
TwitterFacebookYouTube
Search...
EPADEPAD
EPAD
European Prevention of Alzheimer's Dementia Consortium
  • Home
  • About
    • Welcome to EPAD
    • Project Objectives
    • Project Structure
    • EPAD Partners
    • Coordination & Management
    • EPAD Q&A
  • Our research
    • Participation in EPAD
      • Participation in EPAD Cohort
      • EPAD Study Visits
      • Trial Locations
      • Participation FAQs
    • The Participant’s Experience
      • The Research Participant Panel
      • EPAD Stories
    • The EPAD platform
      • The EPAD Platform
      • EPAD Benefits
      • Clinical Candidate Selection
      • EPAD FAQs
      • Research Resources
  • Open Access Data
    • Overview
    • Access
    • Data
    • MRI Images
  • Sample Access
  • News & Publications
    • Latest News
    • Newsletters
    • Publications
    • Videos
Menu back  

The EPAD genomic data is now available on the Alzheimer’s Disease Workbench

2022-03-10News

The European Prevention of Alzheimer’s Dementia (EPAD) consortium, in their partnership with Aridhia and Alzheimer’s Disease Data Initiative (ADDI), are delighted to announce that the EPAD genomic data has been incorporated into the Alzheimer’s Disease (AD) Workbench to provide even greater value to the global neuroscience research community.

A key achievement of the EPAD project was the establishment of a Longitudinal Cohort Study (LCS) that has screened over 2,000 participants and collected a wide range of cognitive, clinical, neuroimaging and biomarker data to help further our understanding of the early stages of Alzheimer’s disease. EPAD has made this database open access and publicly available to the research community through the AD Workbench, which is an open, global and free cloud-based platform for scientists to accelerate discoveries and innovations for AD and related dementias.

This incredibly rich data source has now been enriched with the EPAD genomic data. It is an important step in continuing to share the EPAD LCS data in the long-term and ensuring that this valuable resource is used by the research community to generate as much knowledge as possible.

“At the heart of the EPAD Programme was an explicit commitment, responsibility and obligation to ensure that the time and effort of research participants and researchers yielded the highest quality outputs of knowledge. The global visibility and ease of access and research which ADDI provides helps us to achieve our objective. This most recent release with genomic data from the EPAD LCS will provide new knowledge to the global research community and marks another major milestone for EPAD. We expect that in the months ahead, new data being collected from further research/analysis of EPAD samples and other programmes run within the Edinburgh Dementia Prevention will utilise the AD workbench making AD data findable, accessible, interoperable and reusable (according to the FAIR principles)”, said Craig Ritchie, Project Coordinator of the EPAD project.

About the EPAD LCS data
The final EPAD dataset (V.IMI) went into open access to all researchers from over the world in November 2020. This contains the final longitudinal data from over 2,000 participants of the EPAD LCS. Screening for the first participant in the LCS occurred in May 2016 and finished in early 2020. A total of 2,096 participants were screened. From these 2,096 participants, EPAD followed up with 1,225 after one year, 421 after two years and 121 after three years.

How to access the EPAD data and samples?
EPAD offers a way of accessing the data, samples and image data collected during the EPAD Longitudinal Cohort Study to academic researchers, institutions and companies from all over the world. This is shared through secure online Workspaces and you will need to make an online request via the Alzheimer’s Disease Workbench. For more information, click here.

Share this post
FacebookTwitterLinkedInGoogle+
Related posts
ADDI NeuroToolKit Data Hackathon
2022-05-17
The Neuronet Coordination and Support Action releases updated Decision Tool for engagement with Regulatory and Health Technology Assessment bodies
2022-05-09
First national follow-on study to EPAD LCS launches
2022-04-07
New paper on the affordances of clinical research participation
2022-01-14
ADDI celebrates one year of achievements
2021-11-17
EPAD announces a new collaboration with Hummingbird Diagnostics
2021-10-19
1 Comment
  1. Pingback: The EPAD genomic data is now available on the Alzheimer’s Disease Workbench

Comments are closed.

Latest News
  • ADDI NeuroToolKit Data Hackathon
    2022-05-17
  • The Neuronet Coordination and Support Action releases updated Decision Tool for engagement with Regulatory and Health Technology Assessment bodies
    2022-05-09
  • First national follow-on study to EPAD LCS launches
    2022-04-07
  • The EPAD genomic data is now available on the Alzheimer’s Disease Workbench
    2022-03-10
  • New paper on the affordances of clinical research participation
    2022-01-14
View the EPAD Brochure
thumbnail of EPAD brochure
Speak to the EPAD team
thumbnail of speech bubbles
Twitter
Twitter
EPAD
EPAD
@IMI_EPAD

Registration is now open for the upcoming #NeuroToolKit Data Hackathon! Join fellow experts and investigate biomarkers in #Alzheimers disease. You'll work with @IMI_EPAD datasets by utilizing @AlzData resources. For more information: ep-ad.org/addi-neurotool… twitter.com/IMI_EPAD/statu…

reply retweet favorite
6:56 am · 2022-05-18
Twitter
EPAD
EPAD
@IMI_EPAD

📢 Four abstracts with @IMI_EPAD data have been accepted for #AAIC22, including 3 posters & 1 oral presentation! Looking forward to meeting you in San Diego! @LuigiLorenzini1 @GregorySarah @fpmaragall @amsterdamumc @CenDemPrevent twitter.com/alzassociation…

reply retweet favorite
10:45 am · 2022-04-28
Twitter
EPAD
EPAD
@IMI_EPAD

The @IMI_EPAD Research Participant Panel has been established to give participants an active role in influencing the design, conduct and reporting of research. Want to know more? Watch this recording. #31AEC @AlzheimerEurope @IMI2_NEURONET @CenDemPrevent youtu.be/GObdDorTOE0?t=…

reply retweet favorite
6:42 am · 2022-04-20
Twitter
EPAD
EPAD
@IMI_EPAD

Listen to @GregorySarah from @CenDemPrevent talking about the associations between stressful life events, #Alzheimer's disease biomarkers and cognition in the @IMI_EPAD Longitudinal Cohort Study at the @AlzheimerEurope conference #31AEC. youtu.be/loZSphK4s9g

reply retweet favorite
9:45 am · 2022-04-11
Twitter
EPAD
EPAD
@IMI_EPAD

We are delighted to announce that the first study participant for the @IMI_EPAD Scotland study was seen today! It is the first national initiative to have started study recruitment. @craig_ritchie68 @CenDemPrevent For more info, visit our website⤵️ ep-ad.org/first-national… pic.twitter.com/4Z46mokA88

reply retweet favorite
12:44 pm · 2022-04-07
Copyright © 2015-2021 EPAD | Created by CMAST and Aridhia
  • Acronyms
  • Legal Notice
  • Privacy Policy
Bottom Menu

efpia-logo EU imi logo

This work has received support from the EU/EFPIA Innovative Medicines Initiative Joint Undertaking EPAD grant agreement nº 115736

This website uses cookies to improve your experience. Accept Read More
Privacy & Cookies Policy

Privacy Overview

This website uses cookies to improve your experience while you navigate through the website. Out of these, the cookies that are categorized as necessary are stored on your browser as they are essential for the working of basic functionalities of the website. We also use third-party cookies that help us analyze and understand how you use this website. These cookies will be stored in your browser only with your consent. You also have the option to opt-out of these cookies. But opting out of some of these cookies may affect your browsing experience.
Necessary
Always Enabled
Necessary cookies are absolutely essential for the website to function properly. This category only includes cookies that ensures basic functionalities and security features of the website. These cookies do not store any personal information.
Non-necessary
Any cookies that may not be particularly necessary for the website to function and is used specifically to collect user personal data via analytics, ads, other embedded contents are termed as non-necessary cookies. It is mandatory to procure user consent prior to running these cookies on your website.
SAVE & ACCEPT